| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Influenza A M1 vaccine (Pascal Biosciences) | Phase 1 Clinical | Pascal Biosciences | Influenza A virus infections | Details | |
| adenovector based vaccine (Pascal Biosciences/University of British Columbia) | Phase 1 Clinical | Nevis Brands Inc | Influenza A virus infections | Details | |
| 90Y-2IT-BAD-Lym-1 | 90Y-2IT-BAD-Lym-1 | Phase 1 Clinical | National Cancer Institute | Lymphoma, Non-Hodgkin | Details |
| Bezetabart debotansine | STRO-001; SP7675; SP-7675; BN-301 | Phase 1 Clinical | Sutro Biopharma Inc | Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma | Details |
| TROP-2-targeted anti-CD74 siRNA (Immunomedics) | Immunomedics Inc | Solid tumours | Details |